

---

**This article is a CME/CE certified activity. To earn credit for this activity visit:  
<http://cme.medscape.com/viewarticle/708767>**

From Medscape Medical News CME

### **Treatment of Acne Rosacea Reviewed CME/CE**

News Author: Laurie Barclay, MD

CME Author: Charles Vega, MD, FAAFP

CME/CE Released: 09/11/2009; Valid for credit through 09/11/2010

September 11, 2009 — Treatment options for acne rosacea seen in the family practice setting are reviewed in an article published in the September 1 issue of *American Family Physician*.

"Rosacea is a common skin condition with characteristic symptoms and signs, including symmetric flushing, stinging sensation, inflammatory lesions (papules and pustules), and telangiectasias on the face," write Constance Goldgar, MS, PA-C; David J. Keahey, MSPH, PA-C; and John Houchins, MD, from the University of Utah Physician Assistant Program in Salt Lake City. "Phymatous changes include thickened skin and large pores. Clinical findings represent a spectrum of disease with one or several predominating characteristics, including a pattern of exacerbations and relative inactivity."

Rosacea is a chronic, and sometimes progressive, dermatosis, typically presenting with central facial erythema involving the nose, forehead, chin, and perioral areas. However, it may also cause inflammation of the eyes and eyelids. Regardless of location, rosacea adversely affects quality of life.

Estimated US prevalence of rosacea is 14 million. Although it occurs more commonly in women and in whites, it can affect other ethnic groups. Typical age of onset is in the 30s.

The differential diagnosis of facial rosacea includes acne vulgaris, systemic lupus erythematosus, polymyositis, sarcoidosis, photodermatitis, drug eruptions (especially from iodides and bromides), skin granulomas, and perioral dermatitis. For ocular rosacea, the differential diagnosis may include staphylococcal and seborrheic blepharokeratoconjunctivitis, and sebaceous gland carcinoma.

Identifying the specific subtype of rosacea allows tailoring treatment to the individual patient, which is most likely to result in effective control. According to the National Rosacea Society, there are 4 subtypes: erythematotelangiectatic, papulopustular, phymatous, and ocular, but these are further classified by severity based on the number of papules/pustules and plaques.

In addition to rosacea classification, other factors determining optimal choice of pharmacotherapy include rosacea severity and response to previous treatment regimens. The quality of studies evaluating rosacea treatments is generally poor, according to a 2005 Cochrane review.

The initial treatment strategy for rosacea, especially for the erythematotelangiectatic and papulopustular

subtypes, is to avoid known triggers or exacerbating factors whenever possible.

For patients with mild rosacea, topical metronidazole, sulfacetamide/sulfur, and azelaic acid are usually effective and carry less risk for adverse events, drug interactions, and antibiotic resistance vs systemic treatments.

The first-line choice for moderate papulopustular rosacea is combination therapy with oral tetracyclines and topical agents. Treatment with metronidazole or other topical agent may help patients maintain remission.

Treatment with long-term oral antibiotics and metronidazole gel may be necessary for patients with ocular involvement. For patients who have ocular rosacea with ophthalmic complications, severe or recalcitrant rosacea, or phymatous changes, referral to a subspecialist is required.

Specific clinical recommendations for practice, and their accompanying level of evidence rating, are as follows:

- Rosacea classification, severity, and response to previous therapeutic regimens should determine choice of pharmacologic treatment (level of evidence, C).
- To reduce rosacea flares, the following measures may be helpful:
  - Using emollient, noncomedogenic moisturizers and mild, fragrance-free, soap-free cleansers with nonalkaline or neutral pH;
  - Protecting against sun exposure with use of broad-spectrum sunscreen containing zinc oxide or titanium dioxide, and wide-brimmed hats; and
  - Avoiding astringents and other skin care products containing alcohol, menthol, eucalyptus oil, clove oil, peppermint, witch hazel, or sodium lauryl sulfate (level of evidence, C).
- For background erythema and telangiectasia, dermatologic laser therapy may be considered (level of evidence, C).
- For mild rosacea, initial pharmacotherapy should include appropriate topical regimens, such as antibiotics, immunomodulators, or retinoids. First-line topical regimens, such as metronidazole, azelaic acid, or sulfacetamide/sulfur, should be applied to affected areas once or twice daily (level of evidence, A).
- For moderate to severe rosacea, first-line pharmacotherapy should include orally administered drugs or combined topical and oral therapy. Tetracycline, doxycycline, and minocycline are among the first-line oral medications. Clinicians should consider subantimicrobial dosing (level of evidence, B).
- Once-daily doxycycline administered at a subantimicrobial dose may reduce inflammatory lesions when given alone or in combination with metronidazole therapy (level of evidence, B).
- Eyelid hygiene with hot compresses, eyelid cleansing, and other appropriate measures, as well as topical agents, should be used to treat mild ocular rosacea (level of evidence, C).
- Oral drug therapy with agents from the tetracycline class should be used to treat moderate ocular rosacea (level of evidence, C).

"Evidence for using oral antibiotics to treat rosacea is limited and is often based on clinical experience or older, low-quality studies instead of on well-designed RCTs [randomized controlled trials," the review authors write. "Initial therapy for moderate to severe rosacea should include oral treatment or a combination of topical and oral treatments. Because rosacea is a chronic disease, the long-term use of antibiotics can lead to adverse effects....One potential management strategy is to taper the dosage of oral antibiotics after six to 12 weeks of successful treatment, transitioning to topical agents only."

*The review authors have disclosed no relevant financial relationships.*

*Am Fam Physician.* 2009;80:461-468. Abstract

### **Additional Resource**

More information on rosacea can be found on The National Rosacea Society Web site.

### **Clinical Context**

Rosacea is characterized by symmetric flushing of the face, inflammatory lesions such as papules and pustules, a stinging sensation, and telangiectasias. According to the authors of the current review, it is more common among white persons vs other ethnicities and is slightly more common among women. Symptoms usually begin among adults in their 30s, although rosacea may be found in younger patients as well.

The majority of the current review highlights treatment options for rosacea. The authors' findings are summarized in the "Study Highlights" section.

### **Study Highlights**

- The most basic treatment of rosacea is avoidance of sun exposure. Sunscreen products that contain zinc oxide or titanium dioxide may be better tolerated by patients with rosacea. Astringents may exacerbate rosacea, and patients should use emollient, noncomedogenic moisturizers.
- Topical treatments are the first-line therapy for mild papulopustular rosacea. Metronidazole and azelaic acid have been approved in the treatment of rosacea. Two trials comparing the 2 treatments demonstrated that azelaic acid was comparable or superior to metronidazole in improving erythema, nodules, papules, and pustules. Azelaic acid is not effective in improving telangiectasias.
- Limited data suggest that sulfacetamide/sulfur cream and benzoyl peroxide/antibiotic gels are effective in the treatment of rosacea.
- Adapalene may improve papules and pustules in cases of rosacea, but not erythema or telangiectasia.
- There is limited evidence regarding the best use of systemic therapy for rosacea. One potential treatment strategy is to use oral antibiotics for 6 to 12 weeks and then transition to topical agents

alone.

- The dose of oral tetracyclines for rosacea should be lower than its indication for bacterial infection. Once-daily doxycycline is sufficient.
- 3 to 4 weeks of treatment with oral tetracyclines are required before substantial improvement occurs. The relapse rate of rosacea 6 months after the termination of tetracycline treatment was 60% in 1 study.
- The study quality of trials with oral clarithromycin and azithromycin for rosacea is poor, but both treatments may be effective.
- Isotretinoin can reduce symptoms of rosacea, including rhinophyma. However, it is unknown whether isotretinoin leads to permanent remission of rosacea.
- In 1 trial comparing topical clindamycin lotion vs oral tetracycline, the topical treatment was superior in eradicating pustules. In another trial, oral tetracycline was similarly effective as metronidazole cream.
- Nearly 60% of patients with rosacea have ocular involvement, and eye symptoms may precede dermatologic symptoms. Physicians caring for patients with ocular rosacea should consider referral to an ophthalmologist.
- Mild ocular rosacea can respond to local treatment with topical agents, such as metronidazole gel, plus warm compresses. Moderate ocular rosacea requires treatment with oral therapy.
- Vascular lasers can improve resistant telangiectasias and erythema of rosacea. Rhinophyma may respond to mechanical dermabrasion.

## Clinical Implications

---

- Rosacea is characterized by symmetric flushing of the face, inflammatory lesions such as papules and pustules, a stinging sensation, and telangiectasias. It is more common among white persons vs other ethnicities and is slightly more common among women. Symptoms of rosacea usually begin among adults in their 30s.
- The primary therapy for mild rosacea is topical treatment with medications such as metronidazole or azelaic acid.

## CME/CE Test

---

Which of the following statements is characteristic of acne rosacea?

- It is usually asymptomatic
- Most patients have inflammatory lesions and telangiectasias
- It is most common among African Americans
- It usually begins in childhood

Which of the following treatments is first-line therapy for mild rosacea?

- Adapalene gel
- Oral doxycycline
- Oral metronidazole for 4 weeks only
- Topical metronidazole

Save and Proceed

**This article is a CME/CE certified activity. To earn credit for this activity visit:**

**<http://cme.medscape.com/viewarticle/708767>**

### **Authors and Disclosures**

As an organization accredited by the ACCME, MedscapeCME requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

MedscapeCME encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

### **Author(s)**

---

#### **Laurie Barclay, MD**

freelance writer and reviewer, MedscapeCME

Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.

### **Editor(s)**

---

#### **Brande Nicole Martin**

is the News CME editor for Medscape Medical News.

Disclosure: Brande Nicole Martin has disclosed no relevant financial information.

### **Nurse Planner**

---

#### **Laurie Scudder, MS, NP**

Laurie E. Scudder, MS, NP, Accreditation Coordinator, Continuing Professional Education Department,

Medscape, LLC; Clinical Assistant Professor, School of Nursing and Allied Health, George Washington University, Washington, DC; Nurse Practitioner, School-Based Health Centers, Baltimore City Public Schools, Baltimore, Maryland

Disclosure: Laurie Scudder, MS, NP, has disclosed no relevant financial information.

## CME Author(s)

---

### Charles P. Vega, MD



Associate Professor and Residency Director, Department of Family Medicine, University of California-Irvine, Irvine California

Charles P. Vega, MD, FAAFP, is an associate professor and residency director in the Department of Family Medicine at the University of California, Irvine.

Disclosure: Charles P. Vega, MD, has disclosed no relevant financial relationships.

## Disclaimer

The material presented here does not necessarily reflect the views of MedscapeCME or companies that support educational programming on [www.medscapecme.com](http://www.medscapecme.com). These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Send press releases and comments to [news@medscape.net](mailto:news@medscape.net).

Medscape Medical News CME © 2009 MedscapeCME

---

**This article is a CME/CE certified activity. To earn credit for this activity visit:  
<http://cme.medscape.com/viewarticle/708767>**

## CME/CE Information

**CME/CE Released: 09/11/2009; Valid for credit through 09/11/2010**

## Target Audience

---

This article is intended for primary care clinicians, dermatologists, ophthalmologists, and other specialists who care for patients with rosacea.

## Goal

---

The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.

---

## Learning Objectives

---

Upon completion of this activity, participants will be able to:

1. Describe the diagnosis and epidemiology of rosacea.
2. Treat rosacea effectively.

---

## Credits Available

---

**Physicians** - maximum of 0.25 *AMA PRA Category 1 Credit(s)*<sup>™</sup>

**Family Physicians** - maximum of 0.25 *AAFP Prescribed credit(s)*

**Nurses** - 0.50 *ANCC Contact Hour(s)* (0 contact hours are in the area of pharmacology)

All other healthcare professionals completing continuing education credit for this activity will be issued a certificate of participation.

Physicians should only claim credit commensurate with the extent of their participation in the activity.

---

## Accreditation Statements

---

### For Physicians

**MedscapeCME**<sup>™</sup> MedscapeCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MedscapeCME designates this educational activity for a maximum of 0.25 **AMA PRA Category 1 Credit(s)**<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity. Medscape News CME has been reviewed and is acceptable for up to 300 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins September 1, 2009. Term of approval is for 1 year from this date. Each issue is approved for .25 Prescribed credits. Credit may be claimed for 1 year from the date of this issue.

Note: Total credit is subject to change based on topic selection and article length.

*AAFP Accreditation Questions*

Contact This Provider

### For Nurses

**MedscapeCME**<sup>™</sup> Medscape, LLC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [CME@medscape.net](mailto:CME@medscape.net)

---

## Instructions for Participation and Credit

---

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit\*:

1. Read the target audience, learning objectives, and author disclosures.
2. Study the educational content online or printed out.
3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. MedscapeCME encourages you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

\*The credit that you receive is based on your user profile.

### **Hardware/Software Requirements**

---

MedscapeCME is accessible using the following browsers: Internet Explorer 6.x or higher, Firefox 2.x or higher, Safari 2.x or higher. Certain educational activities may require additional software to view multimedia, presentation or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Macromedia Flash, Adobe Acrobat, or Microsoft PowerPoint.

**Developed and funded by**

**Medscape**